Morphine Syrup Dosage for Severe Pain Management
For severe pain management, oral morphine syrup should be initiated at 20-40 mg every 4 hours with rescue doses of 10-15% of the total daily dose available hourly for breakthrough pain. 1, 2
Initial Dosing and Titration
- Oral morphine is the first-line strong opioid for moderate to severe cancer pain due to its effectiveness, tolerability, simplicity of administration, and cost-effectiveness 1
- For opioid-naïve patients with severe pain, start with:
- For patients with urgent severe pain requiring immediate relief, intravenous administration is preferred:
Dose Conversion and Adjustments
- When converting between routes:
- Titration process:
Maintenance Therapy
- After titration, the total daily dose can be calculated and converted to a modified-release formulation 1
- Continue to provide immediate-release morphine syrup for breakthrough pain at 10-15% of the total daily dose 1
- No upper limit exists for morphine dosing; the appropriate dose is one that provides adequate analgesia with acceptable side effects 1, 2
- Most patients with cancer pain achieve adequate relief with doses between 100-250 mg daily, though doses can range from 25-2000 mg 3
Management of Side Effects
- Common adverse effects include:
- For intolerable side effects:
Special Considerations
- In renal impairment, use reduced doses and frequency 1
- For patients unable to take oral medication, consider subcutaneous route as first alternative 1
- Monitor closely for respiratory depression, especially within the first 24-72 hours of initiating therapy 2
- Be vigilant for signs of neuroexcitatory side effects (myoclonus, seizures) which may occur with high doses or accumulation of metabolites 4
Common Pitfalls to Avoid
- Inadequate breakthrough dosing (should be 10-15% of total daily dose) 1
- Insufficient dose titration leading to uncontrolled pain 2
- Failure to prophylactically manage constipation 1
- Abandoning morphine too quickly due to side effects rather than managing them appropriately 1
- Excessive sedation when converting from immediate-release to extended-release formulations without dose adjustment 2